EMEA-002296-PIP01-17-M03
Key facts
Invented name |
Alunbrig
|
Active substance |
brigatinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0405/2021
|
PIP number |
EMEA-002296-PIP01-17-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Takeda Pharm A/S
E-mail: medinfoEMEA@takeda.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|